Compare Eli Lilly And Co (LLY) vs ProShares Ultra Semiconductors (USD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs ProShares Ultra Semiconductors — how do they compare? Eli Lilly And Co trades at $1,173.98 (market cap $1.04T), while ProShares Ultra Semiconductors trades at $95.02 (market cap $2.94B). The key difference: Eli Lilly And Co is far larger — about 353.7× ProShares Ultra Semiconductors's market cap, and Eli Lilly And Co pays a 0.59% dividend while ProShares Ultra Semiconductors pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and ProShares Ultra Semiconductors for 29 Days on average.
| LLY | USD | |
|---|---|---|
Market Cap | $1.04T | $2.94B |
Volume | 3,064,878 | 630,148 |
Sector | Health | Leveraged / Inverse |
52-Week High | $1.28K | $113.53 |
52-Week Low | $799.57 | $43.19 |
Typical Hold Time | 93 Days | 29 Days |
Enterprise Value | $1.09T | — |
Dividend Yield | 0.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,176.69, down 1.01% on the day, amid a bullish technical outlook and strong fundamental performance. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 consensus. Revenue surged to $65.18B in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing growth prospects.
The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include elevated valuation multiples and competitive pressures in the pharmaceutical sector. With a consensus price target of $1,350, upside potential exists, but investors should weigh execution risks against the company's innovation pipeline.
USD stock trades at $102.77, down 0.96% on the day, with a bullish technical signal driven by strong moving average alignment. The stock shows overbought conditions on shorter-term RSI readings while maintaining positive momentum indicators. Recent corporate actions include a scheduled dividend payment of $0.13 per share for September 2026. Price levels indicate support near $100-$102 and resistance at $103-$105.
The stock's technical strength contrasts with limited fundamental data availability. Investors face uncertainty regarding valuation metrics and profitability measures, requiring careful assessment of upcoming financial disclosures. Near-term price action will likely hinge on market sentiment and technical levels given the current information gap on core business fundamentals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About ProShares Ultra Semiconductors
USD is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the Dow Jones U.S. Semiconductors™ Index. It is a tactical instrument designed for sophisticated traders looking to magnify short-term bullish views on the U.S. semiconductor industry, specifically focusing on large-cap leaders in the chip and equipment space.
Read more on USD →
